Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Clin Oncol. 2012 Jul 20;30(21):2624-34. doi: 10.1200/JCO.2011.41.1140.

2.

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524.

3.

Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.

Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD.

J Am Geriatr Soc. 2009 Aug;57(8):1403-10. doi: 10.1111/j.1532-5415.2009.02355.x.

PMID:
19563521
4.

Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Clin Colorectal Cancer. 2013 Jun;12(2):113-21. doi: 10.1016/j.clcc.2012.09.007.

PMID:
23137529
5.
6.

Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.

Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO, Loconte NK, Greenberg CC, Smith MA.

Ann Surg Oncol. 2014 Jun;21(6):1781-91. doi: 10.1245/s10434-014-3631-8.

7.

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group..

J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. doi: 10.1093/jnci/djr310.

8.

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.

Cancer. 2012 Sep 1;118(17):4309-20. doi: 10.1002/cncr.27422.

9.

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA.

J Clin Oncol. 2011 Sep 1;29(25):3381-8. doi: 10.1200/JCO.2010.34.3426.

10.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238.

PMID:
26527776
11.

Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.

Hanna NN, Onukwugha E, Choti MA, Davidoff AJ, Zuckerman IH, Hsu VD, Mullins CD.

Colorectal Dis. 2012 Jan;14(1):48-55. doi: 10.1111/j.1463-1318.2011.02545.x.

PMID:
21689262
12.

Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.

Mack CD, Carpenter W, Meyer AM, Sanoff H, Stürmer T.

Cancer. 2012 Jun 1;118(11):2925-34. doi: 10.1002/cncr.26622.

13.

Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.

Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2015 Dec;14(4):262-8.e1. doi: 10.1016/j.clcc.2015.05.010.

PMID:
26123496
14.

Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.

Park YS, Ji J, Zalcberg JR, El-Serafi M, Buzaid A, Ghosn M.

Asia Pac J Clin Oncol. 2015 Dec;11(4):334-42. doi: 10.1111/ajco.12409.

PMID:
26471890
15.

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG.

J Clin Oncol. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107.

PMID:
26324362
16.

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Zaanan A.

J Natl Cancer Inst. 2016 Feb 1;108(7). pii: djv438. doi: 10.1093/jnci/djv438.

PMID:
26839356
17.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ.

Ann Oncol. 2015 Apr;26(4):715-24. doi: 10.1093/annonc/mdv003.

18.

Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.

Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, Sandler RS, Stürmer T.

Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):810-8. doi: 10.1002/pds.3386.

20.

Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon Cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Am J Ther. 2016 May-Jun;23(3):e720-9. doi: 10.1097/MJT.0000000000000015.

PMID:
24368611

Supplemental Content

Support Center